GANX News and Press, Gain Therapeutics Inc. From 09/06/22

BETHESDA, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sit...

B. Riley Securities downgraded the development stage biotech Gain Therapeutics, Inc. ( NASDAQ: GANX ) to Neutral from Buy on Friday, noting a material delay in the company's plans to seek regulatory clearance to start clinical trials for the Parkinson's disease lead candidate, G...

BETHESDA, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding site...

BETHESDA, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding site...

BETHESDA, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding site...

Insiders once again significantly stepped up their insider purchases for a third week in a row. 897 insiders across 381 companies purchased $324 million worth of stock last week. There were additional insider purchases at American Homes 4 Rent. For further details see: I...

BETHESDA, Md., May 18, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites...

Gain Therapeutics press release (NASDAQ:GANX): Q1 GAAP EPS of -$0.28 beats by $0.09. Revenue of $0.05M (-99.1% Y/Y) beats by $0.01M. For further details see: Gain Therapeutics GAAP EPS of -$0.28 beats by $0.09, revenue of $0.05M beats by $0.01M

Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in Parkinson’s Disease and Gaucher’s Disease. $34.34 Million in Cash as of March 31, 2022, Provides Runway into Se...

BETHESDA, Md., May 11, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites...